News Conference News Watchman, Amulet LAA Closure Devices Carry Low Complication Rates Todd Neale November 04, 2016
News Conference News TCT 2016 Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making Yael L. Maxwell November 02, 2016
Presentation TCT 2016 Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials Presenter: Helene Eltchaninoff, Neal S. Kleiman, Andreas Baumbach November 01, 2016
Presentation TCT 2016 What Should Be the Next Series of Clinical Trials in PFO Closure? Presenter: Eustaquio Maria Onorato, Richard Smalling, John D. Carroll November 01, 2016
Presentation TCT 2016 What Do the Randomized Clinical Trials Tell Us and How Did the FDA Respond? Presenter: John D. Carroll, Christian Spies November 01, 2016
News Conference News TCT 2016 Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence Todd Neale November 01, 2016
News Conference News TCT 2016 Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint Shelley Wood November 01, 2016
News Industry News Five Year Echocardiogram Follow-Up Data Demonstrates Sustained Durability After Transcatheter Aortic Valve Replacement In High-Risk And Inoperable Patients November 01, 2016
Presentation TCT 2016 PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas November 01, 2016
Presentation TCT 2016 PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen November 01, 2016
Presentation TCT 2016 Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno October 31, 2016
Presentation TCT 2016 Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia October 31, 2016
Presentation TCT 2016 TMVR Clinical Trial Design: Early Insights from Industry Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans October 30, 2016
Presentation TCT 2016 TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja October 30, 2016
Presentation TCT 2016 FDA Perspectives Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger October 30, 2016
Presentation TCT 2016 Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness) Presenter: Vivek Y. Reddy, Steven J. Yakubov October 30, 2016
Presentation TCT 2016 Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali October 30, 2016
News Opinion Editor's Corner TCT 2016 TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever Shelley Wood October 24, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2016 Shelley Wood September 30, 2016
News Daily News Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health Yael L. Maxwell September 26, 2016